RecruitingRecruiting
A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes
NCT07748208 · Hoffmann-La Roche
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Phase II Prospective, Open-Label Safety Study of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With PIK3CA-Mutated Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer and Type 2 Diabetes
About this study
This study will evaluate the safety of inavolisib in combination with fulvestrant, with or without palbociclib, in participants with PIK3CA-mutated, HR+, HER2-negative ABC and type 2 diabetes.
Eligibility criteria
Inclusion Criteria:
* Type 2 diabetes with laboratory fasting blood glucose \< 185 milligrams per deciliter (mg/dL) and HbA1c \<= 8% on any stable anti-hyperglycemic regimen excluding insulin short-term insulin dosing
* Eligible for triplet of inavolisib, fulvestrant and palbociclib: no prior systemic therapy for locally advanced unresectable or metastatic disease
* Confirmed diagnosis of HR+/HER2- breast cancer
* Confirmation of biomarker eligibility (detection of specified mutation(s) of PIK3CA via specified test)
* Measurable disease per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
* Adequate hematologic and organ function within 14 days prior to initiation of study treatment
Exclusion Criteria:
* Pregnant or breastfeeding, or intention of becoming pregnant during the study or within the time frame in which contraception is required
* Metaplastic breast cancer
* Any history of Type 1 diabetes
* Severe hyper- or hypoglycemia event within 6 months of initiation of study treatment
* Any history of leptomeningeal disease or carcinomatous meningitis
* Known and untreated, or active central nervous system (CNS) metastases Participants with a history of treated CNS metastases are eligible
* Active inflammatory or conditions in either eye or history of idiopathic or autoimmune-associated uveitis in either eye
* Symptomatic active lung disease
* History of active bowel inflammation or active inflammatory bowel disease
Study design
Enrollment target: 40 participants
Allocation: na
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-11-30
Estimated completion: 2029-09-30
Last updated: 2026-11-13
Interventions
Drug: InavolisibDrug: FulvestrantDrug: Palbociclib
Primary outcomes
- • Percentage of Participants With Grade 4 Hyperglycemia Adverse Events (AEs) After Cycle 1 (Up to approximately 21 months)
- • Percentage of Participants Hospitalized for Hyperglycemia or its Complications After Cycle 1 (Up to approximately 21 months)
- • Percentage of Participants with AEs After Cycle 1 (Up to approximately 21 months)
Sponsor
Hoffmann-La Roche · industry
Contacts & investigators
ContactReference Study ID Number: GO45322 https://forpatients.roche.com/ No attachments to email below. · contact · global-roche-genentech-trials@gene.com · 888-662-6728 (U.S. and Canada)
ContactFastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry · contact
InvestigatorClinical Trials · study_director, Hoffmann-La Roche
All locations (13)
Community Cancer Institute (CCI)Recruiting
Clovis, California, United States
The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical CenteRecruiting
Torrance, California, United States
MedStar Washington Hosp CenterRecruiting
Washington D.C., District of Columbia, United States
Grady Memorial HospitalRecruiting
Atlanta, Georgia, United States
Emory University Hospital MidtownRecruiting
Atlanta, Georgia, United States
Emory University HospitalRecruiting
Atlanta, Georgia, United States
Nebraska Cancer Specialists St Francis - Grand IslandRecruiting
Grand Island, Nebraska, United States
Nebraska Cancer SpecialistsRecruiting
Omaha, Nebraska, United States
NYU Langone Hospital Long Island Clinical ResearchRecruiting
Mineola, New York, United States
NYU Langone?s Perlmutter Cancer Center - 160 E 34th StRecruiting
New York, New York, United States
West Cancer Center & Research InstituteRecruiting
Germantown, Tennessee, United States
West Virginia UniversityRecruiting
Morgantown, West Virginia, United States
Pan American Center for Oncology Trials, LLCRecruiting
Dorado, Puerto Rico